StreetInsider.com News Articles

Form 8-K Inmune Bio, Inc. For: Oct 21

Wed, 21 Oct 2026 09:01:00 -0400

si-local-file:///var/storage/secattach/20261021/27214122.html

INmune Bio submits pre-MAA package for Ebstrocel, targets mid-2027 UK approval

Wed, 21 Oct 2026 07:16:08 -0400

INmune Bio Inc. (NASDAQ: INMB) announced it submitted its final pre-Marketing Authorisation Application package to the UK Medicines and Healthcare products Regulatory Agency on Oct. 20, 2026, for Ebstrocel (CORDStrom), an investigational cell therapy for recessive dystrophic epidermolysis bullosa.

The Boca Raton, Fla.-based company said it plans to submit a complete MAA in early February 2027, replacing a previously planned rolling submission that was set to begin in late 2026. The company said faster-than-expected manufacturing progress in chemistry, manufacturing and controls enabled the revised approach, which it estimates could bring potential UK approval approximately six weeks earlier than previously anticipated, targeting

INmune Bio submits pre-MAA package for Ebstrocel, targets mid-2027 UK approval

Wed, 21 Oct 2026 07:16:08 -0400

INmune Bio Advances Ebstrocel™ Toward Potential UK Approval in Mid-2027

Wed, 21 Oct 2026 07:15:00 -0400

Final pre-MAA package submitted to MHRA on October 20, 2026
Full MAA submission targeted for early February 2027, under a revised strategy that could bring potential UK approval forward by approximately six weeks
U.S. BLA expected to be submitted in Q2, 2027

BOCA RATON, Fla., Oct. 21, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced that it has submitted its final pre-Marketing Authorisation Application (pre-MAA) package to the UK Medicines and Healthcare products Regulatory Agency (MHRA) for Ebstrocel™ (CORDStrom™), its investigational cell therapy

INmune Bio Advances Ebstrocel™ Toward Potential UK Approval in Mid-2027

Wed, 21 Oct 2026 07:15:00 -0400

Final pre-MAA package submitted to MHRA on October 20, 2026
Full MAA submission targeted for early February 2027, under a revised strategy that could bring potential UK approval forward by approximately six weeks
U.S. BLA expected to be submitted in Q2, 2027

INmune Bio signs distribution deal with Uniphar for Ebstrocel access

Wed, 21 Oct 2026 07:00:16 -0400

INmune Bio Inc. (NASDAQ: INMB) has entered into a Master Services Agreement with Uniphar Durbin Ireland Limited to support international access, distribution, and commercialization of Ebstrocel™, the company's allogeneic stromal cell therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB), according to a press release.

The agreement establishes a framework initially targeting named-patient access in selected European countries and the Middle East and North Africa (MENA) region, subject to applicable local laws and country-specific statements of work. The relationship may expand to broader commercial distribution as regulatory approvals, pricing, and reimbursement are secured in individual countries.

Under the arrangement, Uniphar may provide services including

INmune Bio Establishes Global Commercialization Framework for Ebstrocel™ Through Strategic Agreement with Uniphar

Wed, 21 Oct 2026 07:00:00 -0400

Initial focus on named-patient access in selected European and MENA markets, providing a capital-efficient foundation for broader commercialization

BOCA RATON, Fla., Oct. 21, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced that it has entered into a Master Services Agreement with Uniphar Durbin Ireland Limited (“Uniphar”) establishing a scalable framework to support international access, distribution and commercialization of Ebstrocel™, the Company’s allogeneic stromal cell therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB). INmune Bio initially intends to use the framework to pursue

INmune Bio Establishes Global Commercialization Framework for Ebstrocel™ Through Strategic Agreement with Uniphar

Wed, 21 Oct 2026 07:00:00 -0400

Initial focus on named-patient access in selected European and MENA markets, providing a capital-efficient foundation for broader commercialization

BOCA RATON, Fla., Oct. 21, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced that it has entered into a Master Services Agreement with Uniphar Durbin Ireland Limited (“Uniphar”) establishing a scalable framework to support international access, distribution and commercialization of Ebstrocel™, the Company’s allogeneic stromal cell therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB). INmune Bio initially intends to use the framework to pursue

INmune Bio and Quantum Computing Inc. partner on Alzheimer's drug research

Wed, 14 Oct 2026 08:45:56 -0400

INmune Bio Inc. (Nasdaq: INMB) and Quantum Computing Inc. (Nasdaq: QUBT) announced a collaboration to apply quantum computing, artificial intelligence, and data analytics to identify potential new applications for XPro1595, INmune Bio's investigational treatment for Alzheimer's disease.

The collaboration will use QCi's Dirac-3S quantum optimization machine alongside AI and conventional analytics to analyze INmune Bio's data from pre-clinical research and four clinical trials, as well as publicly available biomedical datasets. The companies intend to use the analysis to identify diseases driven by the same biological mechanisms targeted by XPro1595 and to prioritize indications with higher potential for development success.

According to the

INmune Bio and Quantum Computing Inc. partner on Alzheimer's drug research

Wed, 14 Oct 2026 08:45:56 -0400

According to the

INmune Bio and Quantum Computing Inc. partner on Alzheimer's drug research

Wed, 14 Oct 2026 08:45:56 -0400

According to the

INmune Bio and Quantum Computing Inc. partner on Alzheimer's drug research

Wed, 14 Oct 2026 08:45:56 -0400

According to the

INmune Bio Inc. and Quantum Computing Inc. Partner to Apply Quantum Optimization and AI to Advance Alzheimer’s Drug Research and Explore New Applications for XPro ™

Wed, 14 Oct 2026 08:45:00 -0400

Collaboration combines INmune Bio's clinical research with QCi's Dirac-3S quantum optimization machine to identify potential new treatment indications and biomarkers for XPro
Initial engagement marks QCi's first commercial customer in pharmaceutical and biotechnology markets, expanding the application of quantum computing to drug development

BOCA RATON, Fla. and HOBOKEN, N.J., Oct. 14, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (Nasdaq: INMB) and Quantum Computing Inc. (Nasdaq: QUBT) today announced a collaboration to apply quantum computing, artificial intelligence (AI) and data analytics to identify new potential applications for

INmune Bio Inc. and Quantum Computing Inc. Partner to Apply Quantum Optimization and AI to Advance Alzheimer’s Drug Research and Explore New Applications for XPro ™

Wed, 14 Oct 2026 08:45:00 -0400

Collaboration combines INmune Bio's clinical research with QCi's Dirac-3S quantum optimization machine to identify potential new treatment indications and biomarkers for XPro
Initial engagement marks QCi's first commercial customer in pharmaceutical and biotechnology markets, expanding the application of quantum computing to drug development

INmune Bio Inc. and Quantum Computing Inc. Partner to Apply Quantum Optimization and AI to Advance Alzheimer’s Drug Research and Explore New Applications for XPro ™

Wed, 14 Oct 2026 08:45:00 -0400

Collaboration combines INmune Bio's clinical research with QCi's Dirac-3S quantum optimization machine to identify potential new treatment indications and biomarkers for XPro
Initial engagement marks QCi's first commercial customer in pharmaceutical and biotechnology markets, expanding the application of quantum computing to drug development

INmune Bio Inc. and Quantum Computing Inc. Partner to Apply Quantum Optimization and AI to Advance Alzheimer’s Drug Research and Explore New Applications for XPro ™

Wed, 14 Oct 2026 08:45:00 -0400

Collaboration combines INmune Bio's clinical research with QCi's Dirac-3S quantum optimization machine to identify potential new treatment indications and biomarkers for XPro
Initial engagement marks QCi's first commercial customer in pharmaceutical and biotechnology markets, expanding the application of quantum computing to drug development

INmune Bio Inc. and Quantum Computing Inc. Partner to Apply Quantum Optimization and AI to Advance Alzheimer's Drug Research and Explore New Applications for XPro ™

Wed, 14 Oct 2026 08:30:00 -0400

Collaboration combines INmune Bio's clinical research with QCi's Dirac-3S quantum optimization machine to identify potential new treatment indications and biomarkers for XPro
Initial engagement marks QCi's first commercial customer in pharmaceutical and biotechnology markets, expanding the application of quantum computing to drug development

INmune Bio Inc. and Quantum Computing Inc. Partner to Apply Quantum Optimization and AI to Advance Alzheimer's Drug Research and Explore New Applications for XPro ™

Wed, 14 Oct 2026 08:30:00 -0400

Collaboration combines INmune Bio's clinical research with QCi's Dirac-3S quantum optimization machine to identify potential new treatment indications and biomarkers for XPro
Initial engagement marks QCi's first commercial customer in pharmaceutical and biotechnology markets, expanding the application of quantum computing to drug development

INmune Bio Inc. and Quantum Computing Inc. Partner to Apply Quantum Optimization and AI to Advance Alzheimer's Drug Research and Explore New Applications for XPro ™

Wed, 14 Oct 2026 08:30:00 -0400

Collaboration combines INmune Bio's clinical research with QCi's Dirac-3S quantum optimization machine to identify potential new treatment indications and biomarkers for XPro
Initial engagement marks QCi's first commercial customer in pharmaceutical and biotechnology markets, expanding the application of quantum computing to drug development

INmune Bio Inc. and Quantum Computing Inc. Partner to Apply Quantum Optimization and AI to Advance Alzheimer's Drug Research and Explore New Applications for XPro ™

Wed, 14 Oct 2026 08:30:00 -0400

Collaboration combines INmune Bio's clinical research with QCi's Dirac-3S quantum optimization machine to identify potential new treatment indications and biomarkers for XPro
Initial engagement marks QCi's first commercial customer in pharmaceutical and biotechnology markets, expanding the application of quantum computing to drug development

INmune Bio to Attend the 2026 Maxim Growth Summit

Tue, 06 Oct 2026 09:00:00 -0400

BOCA RATON, FL, Oct. 06, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, is excited to announce its participation in the upcoming 2026 Maxim Growth Summit, taking place from October 12th to 14th at The Hard Rock Hotel NYC. This prestigious event brings together industry leaders, innovators, and premier institutions to explore the latest trends and advancements across several industries.

INmune Bio will be meeting with institutional investors in one-on-one sessions and engaging with senior Maxim research analysts throughout the event. Company CEO David

INmune Bio to Attend the 2026 Maxim Growth Summit

Tue, 06 Oct 2026 09:00:00 -0400

INmune Bio will be meeting with institutional investors in one-on-one sessions and engaging with senior Maxim research analysts throughout the event. Company CEO David

Form 4 Inmune Bio, Inc. For: Sep 15 Filed by: Clark Ronnie Duane

Wed, 23 Sep 2026 06:06:00 -0400

si-local-file:///var/storage/secattach/20260923/27092974.html

Form 3 Inmune Bio, Inc. For: Sep 08 Filed by: Clark Ronnie Duane

Wed, 23 Sep 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260923/27092948.html

Form 8-K Inmune Bio, Inc. For: Sep 08

Tue, 22 Sep 2026 17:10:00 -0400

si-local-file:///var/storage/secattach/20260922/27091857.html